



Review Article

The Role of Probiotics in Parkinson's Disease: A Review Study

MH Mubarak Shaden¹, Ekrahi Mohammad², Bathiha Gaber El-Saber³, Memariani Mojtaba⁴, Memariani Hamed⁴, Ghasemian Abdolmajid^{5*}

1. Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University Of Kufa, Iraq
2. Department of Infectious Diseases, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran
3. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour22511, AlBeheira, Egypt
4. Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. Noncommunicable Diseases Research Center, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran

Received: 27 Jun 2021

Accepted: 10 Jul 2021

Abstract

An upward trend in the incidence of Parkinson's disease (PD), known as one of the most prominent neurodegenerative maladies, has evoked great concerns among medical community over the past decades. Recently, studies have suggested the initiation of PD in the gastrointestinal tract decades before the advent of manifestations. Accumulating evidence suggests that intracellular deposition of α -synuclein (α -syn) in patients with PD is associated with systemic inflammation leading to the neuroinflammation and neuropsychiatric disorders. The α -syn protein accumulation can be initiated from GI cells and distribute into CNS cells through trans-synaptic cell to cell transmission. Without doubt, gut microbiota affects the enteric nervous system (ENS) known as the "second brain". Patients with PD have a different balance of bacteria in their intestines, as compared to healthy population. Metabolites from gut microbiota affect the enteric wall such as neurodegeneration. Probiotics have a substantial role in the neutralization or inhibition of reactive oxygen species (ROS) and free radicals and thus improve the PD symptoms. The anti-inflammatory role of probiotics also inhibits the neurodegeneration and PD development. Hence, probiotics contribute to the improvement of PD through several mechanisms which need more in-depth verification.

Keywords: Probiotics, Parkinson's disease, Microbiome, inhibitory mechanisms

Introduction

Parkinson's disease (PD) is developed due to the depletion of dopaminergic neurons in the dense region of the substantia nigra in the brainstem (1, 2). The PD signs mostly include the manifestation of symptoms such as tremors, bradykinesia, muscle

stiffness, vibration during rest, cognitive and behavioral impairs, autonomic system disorders, and sleep disturbances (3). These changes give rise to functional motor asymmetry, which is commonly measured by the induction of rotation to the same side (ipsilateral) and to the opposite side (contralateral) by direct dopaminergic agonists (apomorphine) and with immediate effect (amphetamine). Regrettably, thus far, there is no therapeutic approach to the disease, and the rate of newly diagnosed cases

***Corresponding Author: Ghasemian Abdolmajid,** Noncommunicable Diseases Research Center, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran
Email: majidghasemian86@gmail.com
<https://orcid.org/0000-0002-1243-6341>

MH Mubarak Shaden: <https://orcid.org/0000-0003-1060-6527>
Memariani Mojtaba: <https://orcid.org/0000-0000-2496-4311>
Bashdar Mahmud Hussen: <https://orcid.org/0000-0002-2395-1701>
Memariani Hamed: <https://orcid.org/0000-0003-1026-140X>
Bathiha Gaber El-Saber: <https://orcid.org/0000-0001-9525-3075>



The brain is highly vulnerable to oxidative damage owing to its high metabolic rate. Protection against free radical oxidative damage in the central nervous system (CNS) can be exerted by low molecular weight antioxidants such as vitamins E and C. The fact that vitamin E acts as a free-radical scavenger in brain tissue has led to the convincing idea that several neurological disorders may be prevented by its properties (4).

Dopamine plays a vital role in various functions of the CNS, including emotion, motor behavior, recognition and regulation of endocrine. Additionally, dopamine is a crucial substrate in synaptic plasticity, memory mechanisms, and learning (5). Extrusions related to the dopaminergic neurons of the abdominal ganglion and the substantia nigra are directed to the hippocampus, dentine, and prefrontal cortex (6). Dopamine secreted from this route in the hippocampus affects memory, in particular spatial and learning memories. Thus, the effect of dopamine on memory is induced by synaptogenesis in the hippocampus (7).

Dopamine precursors, analogues, and agonists have been extensively employed for the treatment of PD. However, there is a limitation in the administration of L-DOPA, the precursor of dopamine. Indeed, its chronic administration is associated with long-term motor impairment. Microbiota are divided into pathogenic and beneficial genera (8-16). The beneficial effects of probiotics in human health, through improving the gut microflora and the immune system and prevention or treatment of various diseases has opened up new avenues for further research on their conceivable prophylactic and therapeutic applications via production of various compounds e.g., vitamins, hormones, hydrogen peroxide, diethyl acetaldehyde, lactoperoxidase, short-chain fatty acids, antioxidants and bacteriocins (17,18). A healthy human gut is teeming with approximately 100 trillion bacteria, all of which together create the intestinal microbiome. Probiotics also contribute to the intestinal pH reduction, the generation of certain gastrointestinal (GI) enzymes, lowering

the LDL cholesterol, preventing bacterial infections, eliminating carcinogenic substances, and improving calcium absorption (19). The differences in the frequency and diversity of mucosal-associated and fecal microbiota between PD patients and healthy subjects has been deciphered. Comparison of 16S ribosomal RNA gene sequences between bacteria isolated from gut of healthy subjects and PD patients has revealed altered abundances in the content of nine genera and 15 species of microorganisms. Such alterations could trigger local inflammation and subsequent aggregation of α -syn, which results in the PD development through deposition of Lewy bodies inside nerve cells (20). The α -syn protein accumulation can be initiated from GI cells and distributed into CNS cells through trans-synaptic cell to cell transmission. Some surveys have also noted an increased population of bacteria belonging to the families *Christensenellaceae* and *Methanobacteriaceae* in PD patients (20). Furthermore, there is ample evidence that exposure to lipopolysaccharide causes neuronal loss through inflammatory circuits and oxidative injury. It has also been shown that fecal short chain fatty acids (SFAs, required for activation of microglial cells) are reduced in PD patients. Interestingly, a shrinking population of SFA-producing bacteria including *Blautia*, *Roseburia*, and *Coproccoccus* species has been observed in fecal samples of PD patients (21-23). On the other hand, dysbiosis causes increased epithelial permeability and inflammation of the gut mucus layer, which then triggers the activation of effector T cells, disrupting their balance with immunosuppressive regulatory T cells leading to improper GI function and homeostatic imbalance (24). Apart from that, impact of demographic factors including age, gender, and race has been still the subject of much debate (25).

Searching strategy

In this study, full text published papers found in searching engines including Google Scholar, Web of Science, SCOPUS and PubMed during the period 2009-2020 were selected. The words

“probiotics”, “Parkinson’s disease”, “mechanism”, “development” and “inhibition” were adopted for searching. Inclusion criteria included those papers which investigated the role of probiotics in the inhibition of Parkinson’s disease. Exclusion criteria included those papers without full text and those publications with therapeutic purposes.

Gut-Brain axis in Parkinson’s disease

Neurodegenerative diseases are characterized by loss of neuronal cells. In the PD, the accumulation of Lewy bodies and Lewy neuritis containing misfolded α -synuclein (α -Syn) affect the substantia nigra and GI nerve cells. The parasympathetic or vagal nerves provide the communication between brain and gut. Therefore, the accumulation of α -Syn in the GI cells prior to the CNS cells, initiates the PD symptoms. Recently, mounting evidence has revealed that PD is also associated with other neuronal systems such as enteric neurons. The GI dysfunction in the early stages of the PD is a significant non-motor symptom mostly with constipation in 80% of patients (2, 26). On the other hand, the gut dysbiosis causes absorption and increase in metabolites from GI tract and causes systemic inflammation. The inflammation of enteric nervous system (ENS) and CNS causes neuroinflammation and damage of neuronal cells which develop the PD (27).

Probiotics species and activities

There is voluminous evidence that probiotics ward off many GI maladies through 1) production of inhibitory compounds (28), 2) competitive blocking of microbial binding sites, 3) nutritional competition with pathogens, 4) elimination of toxins receptors, 5) stimulation of immune responses, and 6) amelioration of inflammatory responses in autoimmune and allergic disorders (16, 29). The sum of all the processes by which bacteria control the colonization of other bacterial species in the body through controlled colonization is known as resistance to colonization. *Bifidobacterium* and *Lactobacilli* are major probiotics species

(30, 31). Probiotics are theorized to exert these inhibitory effects in several ways. The probiotics employment in preventing diseases and improving the health status has a long history. Probiotics are used not only as a growth stimulant, but also for inducing the immune system and preventing the spread of numerous diseases. These live microorganisms help maintain or increase the growth of livestock and humans in order to replace or strengthen the beneficial microorganisms in the GI tract (32).

Several *in vivo* studies have assessed the beneficial role of probiotic bacteria such as *Lactobacillus casei* Shirota ($1 \times$ daily for 5 weeks, 6.5×10^9 CFU), *Streptococcus salivarius* subsp. *thermophilus*, *Enterococcus faecium*, *Lactobacillus rhamnosus* GG, *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Lactobacillus paracasei*, *Lactobacillus delbrueckii*, subsp. *bulgaricus*, and *Bifidobacterium* (fermented milk) in PD animal models (33-36). In addition, FMT has been applied ($1 \times$ daily for 7 days 2×10^7 CFU) (37). Among these microorganisms, *L. brevis* is considered to be one of the most prominent members of the probiotic bacterial group (38), firstly isolated from milk and broadly used as an initiator in dairy, meat, vegetable, and cereal industries. Considering the emotional, economic, and psychological effects of PD in community, some desirable features of probiotics, especially low cost and availability, make them as an auspicious agent for the prevention, treatment, and control of numerous diseases. Therefore, unraveling the exact association of probiotics in the improvement or the prevention of PD seems a chief requirement.

Anti-inflammatory effects of probiotics

The colonizing probiotics have crucial role in the control of autoimmune diseases due to regulatory role of immune system via host-bacteria relation (39). The intestinal epithelium encompasses higher number of immune cells compared to the secondary lymphoid tissue. One possible mechanism for lower inflammatory

responses against host microbiota is that they lack stimulating antigens (39). Noticeably, microbiota affects the differentiation of immune cells having a reciprocal relationship. More relevantly, some species of bacteria cause the stability and function of helper T (T-h) and regulatory-T (T-reg) cells in the lamina propria (LP). It was observed that *Bacterioides fragilis* affects the immune responses (39, 40). It has also been verified that intestinal microbiota effects the arthritis through regulation of Th cells population (41).

Probiotics mechanisms in the PD improvement

There is growing evidence on the link between imbalance of the gut microbiota and certain maladies such as constipation and malnutrition. Fecal microbiota transplantation (FMT) is a procedure that delivers stool from healthy donors to patients with an altered colonic microbiome to restore the normal population of bacteria. While *Clostridium difficile* is the only condition for which FMT is currently used, others such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and PD are also being considered (27, 42, 43).

Oligomerization and accumulation of α -syn play a critical role in the progression of PD and other neurodegenerative diseases (44). Furthermore, α -syn increase owing to GI tract microbiota dysbiosis by genetic or environmental factors gives rise to disruption of ENS, abnormal

intestinal permeability, and endotoxemia, highlighting the prohibitory effects of residing microbiota (44, 45). In a study, the treatment of PD patients with probiotics significantly improved the consistency and life quality associated with the constipation outcomes (45). In another study, application of SLAB51 probiotic strain decreased the harmful effects due to the PD *in vitro* and *in vivo* (46).

Since oxidative stress is a potential mechanism contributing to the pathogenesis of PD, numerous studies have investigated the disclosure of the antioxidant effects of various natural products for PD prevention. Among the dietary antioxidants, Vitamins C and E, and carotenoids (β -carotene) exhibit protective effects on cells from oxidative damage. In this respect, there is an inverse association between the intake of vitamin E and the risk of PD development, but no relationship between the intake of vitamin C and β -carotene with the PD has been observed. Probiotics can confer therapeutic effects on PD by production of metabolites and vitamins such as vitamin E (Figure1) (47). Some studies have revealed elevated levels of free iron in basal complexes of patients with PD. Free iron catalyst enhances a reaction for the production of free radicals and is involved in lipid peroxidation and neuro-degeneration. Probiotics also have the potential to neutralize these radicals by producing antioxidant metabolites (48).




Figure1. The cellular mechanisms of probiotics metabolites on neurodegeneration or neuroinflammation following gut dysbiosis in PD pathogenesis; α -syn aggregation and its transfer through vagal nerve (gut-brain axis) to substantia nigra is the major cause of PD development. This phenomenon occurs because of different factors such as malnutrition, antibiotic consumption, oxidative stress, SCFA decrease, gut inflammation (due to pathogens; increase of neuromodulatory factors), and constipation (49)

In all of the synapses where a neuron terminates in a skeletal muscle, acetylcholine exists, thus PD can be observed as a kind of dopamine imbalance with acetylcholine, and notably recent studies have revealed that probiotics can help its balance in the body (50).

Oxidative stress increased lipid peroxidation, and reduced glutathione levels are common factors influencing the degeneration of dopaminergic neurons. Furthermore, free radicals directly cause cellular damage and affect DNA, proteins and lipids, causing lipid peroxidation and ultimately inducing cellular apoptosis (51). It has been revealed that probiotics contain antioxidant properties by producing antioxidant metabolites, regulating the activity of antioxidants, increasing the antioxidant enzymes through several signaling pathways, and reducing the reactive oxygen species (ROS) levels (52, 53). The antioxidants protect nerve cells through various mechanisms, such as stimulating neuronal regeneration and enhancing the function of remaining neurons. Another study clarified that oxidative stress is substantially effective in the pathogenesis and complications due to the PD and vitamins produced by probiotics have the potential role in the improvement of the PD symptoms through oxidative stress inhibition (54, 55). Therefore, consumption of compounds that can inhibit the effect of oxidants can improve memory, intelligence as well as muscle stiffness in PD and also prevent the destruction of neurons (56). Other studies have revealed that probiotics can act as anti-inflammatory agents which inhibit neuroinflammation (49). In this respect, these effects are conferred through the inhibition of the prostaglandins and leukotrienes production, which in turn, has a positive effect on inflammation decreasing and accordingly, probiotics can reduce the PD through this mechanism (31-33).

Conclusion

The Gut-brain bidirectional relation contributes to PD development. Probiotics are beneficial choices for therapy of GI disorders,

though not still considered a panacea owing to data paucity. Accumulating evidence suggests that intracellular deposition of α -syn in patients with PD is associated with intestinal dysbiosis. Undoubtedly, gut microbiota plays a crucial role in fermenting unused energy substrates, influencing the maturation of the immune system, and producing vitamins, hormones and balance of the acetylcholine. Probiotics have a substantial role in the neutralization or inhibition of ROS and free radicals and thus improve the PD symptoms. The anti-inflammatory role of probiotics also inhibits neurodegeneration and PD development. More detailed studies on the signaling of the gut-brain axis should be incorporated. The α -syn protein accumulation can be initiated from GI cells and distributed into CNS cells through the trans-synaptic cell to cell transmission.

Acknowledgments

This study was written by the authors.

Conflict of interest

None to declare

References

1. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. *The Lancet Neurology*. 2016;15(12):1257-72.
2. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and metaanalysis. *Movement Disorders*. 2014; 29(13):1583-1590.
3. Bellomo G, Paolini Paoletti F, Chipi E, Petricciuolo M, Simoni S, Tambasco N, et al. A/T/(N) profile in cerebrospinal fluid of Parkinson's disease with/without cognitive impairment and dementia with lewy bodies. *Diagnostics*. 2020;10(12):1015.
4. de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. *Annals of neurology*. 2011;69(5):803-10.
5. Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. *Cell stem cell*. 2015;16(3):269-74.
6. Claassen DO, Stark AJ, Spears CA, Petersen KJ, van Wouwe NC, Kessler RM, et al. Mesocorticolimbic



hemodynamic response in Parkinson's disease patients with compulsive behaviors. *Movement Disorders*. 2017;32(11):1574-83.

7. Wakade C, Giri B, Malik A, Khodadadi H, Morgan JC, Chong RK, et al. Niacin modulates macrophage polarization in Parkinson's disease. *Journal of neuroimmunology*. 2018;320:76-9.

8. Moreadith RW, Viegas TX, Bentley MD, Harris JM, Fang Z, Yoon K, et al. Clinical development of a poly (2-oxazoline)(POZ) polymer therapeutic for the treatment of Parkinson's disease—Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. *European Polymer Journal*. 2017;88:524-52.

9. Al-Bdery ASJ, Mohammad GJ, Hussen B. Vancomycin and linezolid resistance among multidrug-resistant *Staphylococcus aureus* clinical isolates and interaction with neutrophils. *Gene Reports*. 2020;21:100804.

10. Ali FA, Hussen BM, Zaki SM. Molecular detection of bla_{ctx-m} gene among *Pseudomonas aeruginosa* strains isolated from different clinical samples in Erbil city. *Annals of Tropical Medicine and Health*. 2020;23:231.

11. Al-Sa'ady AT, Mohammad GJ, Hussen BM. Genetic relation and virulence factors of carbapenemase-producing Uropathogenic *Escherichia coli* from urinary tract infections in Iraq. *Gene Reports*. 2020;21:100911.

12. Balaky STJ, Abdulkhalik H, Hussen BM, Hassan H, Mawlood AH. Molecular Identification of *Acinetobacter baumannii* and *Acinetobacter* genomic species 13TU Using PCR. *Zanco Journal of Pure and Applied Sciences*. 2019;31(1):17-22.

13. Hamadamin HA, Baban ST, Hussen BM, Ali FA. Distribution of bla_{TEM} Gene among *Escherichia Coli* Strains Isolated from Different Clinical Samples in Erbil City. *Journal of Kirkuk Medical College Vol*. 2019;7(1):17-23.

14. Hussen BM. Evaluating the prevalence of virulence factor gene and biofilm production in *Pseudomonas aeruginosa* isolated from different clinical samples. *Zanco Journal of Pure and Applied Sciences*. 2020;32(4):108-13.

15. Nanakaly HT, Hussen BM. Seroprevalence of Cytomegalovirus Among Voluntary Blood Donors in Erbil Province, North Iraq. *Zanco Journal of Pure and Applied Sciences*. 2019;31(3):1-6.

16. Ghasemian A, Eslami M, Shafiei M, Najafipour S, Rajabi A. Probiotics and their increasing importance in human health and infection control. *Reviews in Medical Microbiology*. 2018;29(4):153-8.

17. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature reviews Gastroenterology & hepatology*. 2014;11(8):506-14.

18. Sanders LH, Greenamyre JT. Oxidative damage to macromolecules in human Parkinson disease and the

rotenone model. *Free Radical Biology and Medicine*. 2013;62:111-20.

19. Oliveira LF, Salvador SL, Silva PH, Furlaneto FA, Figueiredo L, Casarin R, et al. Benefits of *Bifidobacterium animalis* subsp. *lactis* Probiotic in Experimental Periodontitis. *Journal of periodontology*. 2017;98:156-204.

20. Petrov V, Saltykova I, Zhukova I, Alifirova V, Zhukova N, Dorofeeva YB, et al. Analysis of gut microbiota in patients with Parkinson's disease. *Bulletin of experimental biology and medicine*. 2017;162(6):734-7.

21. Becker A, Faßbender K, Oertel WH, Unger MM. A punch in the gut—Intestinal inflammation links environmental factors to neurodegeneration in Parkinson's disease. *Parkinsonism & related disorders*. 2018.

22. Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. *Gut*. 2019; 68(5):829-43.

23. Cox LM, Weiner HL. Microbiota signaling pathways that influence neurologic disease. *Neurotherapeutics*. 2018;15(1):135-45.

24. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson's disease. *Movement Disorders*. 2015;30(10):1351-60.

25. Riley M, Bakeberg M, Byrnes M, Jefferson A, Ghosh S, Stell R, et al. Demographic and clinical predictors of trait impulsivity in Parkinson's disease patients. *Parkinson's Disease*. 2018;23(9):1-7.

26. Gorecki AM, Dunlop SA, Rodger J, Anderton RS. The gut-brain axis and gut inflammation in Parkinson's disease: stopping neurodegeneration at the toll gate. *Expert opinion on therapeutic targets*. 2020;24(7):601-4.

27. Gazerani P. Probiotics for Parkinson's disease. *International journal of molecular sciences*. 2019;20(17):4121.

28. Grotkjær T, Bentzon-Tilia M, D'Alvise P, Dourala N, Nielsen KF, Gram L. Isolation of TDA-producing *Phaeobacter* strains from sea bass larval rearing units and their probiotic effect against pathogenic *Vibrio* spp. in *Artemia* cultures. *Systematic and applied microbiology*. 2016;39(3):180-8.

29. Yousefi B, Eslami M, Ghasemian A, Kokhaei P, Salek Farrokhi A, Darabi N. Probiotics importance and their immunomodulatory properties. *Journal of cellular physiology*. 2018; 234(6):8008-18

30. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. *npj Parkinson's Disease*. 2021;7(1):1-3.

31. Shirazi MSR, Al-Alo K, Al-Yasiri MH, Lateef ZM, Ghasemian A. Microbiome Dysbiosis and Predominant Bacterial Species as Human Cancer Biomarkers. *Journal of Gastrointestinal Cancer*. 2019; 51(3):725-8.

32. Oroojalian F, Kasra-Kermanshahi R, Azizi M, Bassami MR. Phytochemical composition of the essential oils from



- three Apiaceae species and their antibacterial effects on food-borne pathogens. *Food chemistry*. 2010;120(3):765-70.
33. Georgescu D, Ancusa OE, Georgescu LA, Ionita I, Reisz D. nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope? *Clinical interventions in aging*. 2016; 11(2):16-21.
34. Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, et al. Use of probiotics for the treatment of constipation in Parkinson's disease patients. *Minerva gastroenterologica e dietologica*. 2011;57(2):117-21.
35. Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. *Neurology*. 2016;87(12):1274-80.
36. Carlucci C, Petrof EO, Allen-Vercoe E. Fecal microbiota-based therapeutics for recurrent *Clostridium difficile* infection, ulcerative colitis and obesity. *EBioMedicine*. 2016;13 (8):37-45.
37. Sun M-F, Zhu Y-L, Zhou Z-L, Jia X-B, Xu Y-D, Yang Q, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF- α signaling pathway. *Brain, behavior, and immunity*. 2018;70 (7):48-60.
38. Kim JY, Lee MY, Ji GE, Lee YS, Hwang KT. Production of γ -aminobutyric acid in black raspberry juice during fermentation by *Lactobacillus brevis* GABA100. *International journal of food microbiology*. 2009;130(1):12-6.
39. Plaza-Díaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, Gil A. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. *Nutrients*. 2017;9(6):55-59.
40. Lorea Baroja M, Kirjavainen P, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. *Clinical & Experimental Immunology*. 2007;149(3):470-9.
41. Bustamante MF, Agustín-Perez M, Cedola F, Coras R, Narasimhan R, Golshan S, et al. Design of an anti-inflammatory diet (ITIS diet) for patients with rheumatoid arthritis. *Contemporary clinical trials communications*. 2020;17:100524.
42. Martarelli D, Verdenelli MC, Scuri S, Cocchioni M, Silvi S, Cecchini C, et al. Effect of a probiotic intake on oxidant and antioxidant parameters in plasma of athletes during intense exercise training. *Current microbiology*. 2011;62(6):1689-96.
43. Gerhardt S, Mohajeri M. Changes of colonic bacterial composition in Parkinson's disease and other neurodegenerative diseases. *Nutrients*. 2018;10(6):708.
44. Castelli V, d'Angelo M, Quintiliani M, Benedetti E, Cifone MG, Cimini A. The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson's disease? *Neural Regeneration Research*. 2021;16(4):628.
45. Tan AH, Lim S-Y, Chong KK, Manap MAAA, Hor JW, Lim JL, et al. Probiotics for constipation in Parkinson's disease: A randomized placebo-controlled study. *Neurology*. 2021; 2;96(5):e772-82.
46. Castelli V, d'Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models. *Aging (Albany NY)*. 2020;12(5):46-51.
47. Ahmadinejad F, Geir Møller S, Hashemzadeh-Chaleshtori M, Bidkhorji G, Jami M-S. Molecular mechanisms behind free radical scavengers function against oxidative stress. *Antioxidants*. 2017;6(3):51.
48. Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson's disease and Parkinsonism. *Journal of Clinical Neuroscience*. 2018; 53 (5):1-5.
49. Vuuren MJv, Nell TA, Carr JA, Kell DB, Pretorius E. Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson's Disease. *Biomolecules*. 2021;11(1):30.
50. Branco RC, Ellsworth W, Niedzwiecki MM, Butkovich LM, Walker DI, Huddleston DE, et al. Levodopa and dopamine dynamics in Parkinson's disease metabolomics. *bioRxiv*. 2018;30(7):62-66.
51. Cristini J, Weiss M, De Las Heras B, Medina-Rincón A, Dagher A, Postuma RB, Huber R, Doyon J, Rosa-Neto P, Carrier J, Amara AW. The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. *Sleep medicine reviews*. 2021;55:101384.
52. Qu X, Liu L, Wang H, Li X, Zhang X, Chen P, et al. Antioxidant capacity of probiotic cheese after simulated gastrointestinal digestion. *Shipin Kexue/Food Science*. 2018;39(3):90-6.
53. De Marco S, Sichetti M, Muradyan D, Piccioni M, Traina G, Pagiotti R, et al. Probiotic Cell-Free Supernatants Exhibited Anti-Inflammatory and Antioxidant Activity on Human Gut Epithelial Cells and Macrophages Stimulated with LPS. *Evidence-Based Complementary and Alternative Medicine*. 2018; 17(5):63-58.
54. Le Barz M, Anhé FF, Varin TV, Desjardins Y, Levy E, Roy D, et al. Probiotics as complementary treatment for metabolic disorders. *Diabetes & metabolism journal*. 2015;39(4):291-303.
55. Bulgarelli D, Rott M, Schlaeppi K, van Themaat EVL, Ahmadinejad N, Assenza F, et al. Revealing structure and assembly cues for *Arabidopsis* root-inhabiting bacterial microbiota. *Nature*. 2012;488(74):91-96.
56. Khodadadian A, Hemmati-Dinarvand M, Kalantary-Charvadeh A, Ghobadi A, Mazaheri M. Candidate biomarkers for Parkinson's disease. *Biomedicine & Pharmacotherapy*. 2018;104(9):699-704.